Loading…
Comparison of in vitro cell models in predicting in vivo brain entry of drugs
Although several in vitro models have been reported to predict the ability of drug candidates to cross the blood–brain barrier, their real in vivo relevance has rarely been evaluated. The present study demonstrates the in vivo relevance of simple unidirectional permeability coefficient ( P app) dete...
Saved in:
Published in: | International journal of pharmaceutics 2010-12, Vol.402 (1), p.27-36 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Although several
in vitro models have been reported to predict the ability of drug candidates to cross the blood–brain barrier, their real
in vivo relevance has rarely been evaluated. The present study demonstrates the
in vivo relevance of simple unidirectional permeability coefficient (
P
app) determined in three
in vitro cell models (BBMEC, Caco-2 and MDCKII-MDR1) for nine model drugs (alprenolol, atenolol, metoprolol, pindolol, entacapone, tolcapone, baclofen, midazolam and ondansetron) by using dual probe microdialysis in the rat brain and blood as an
in vivo measure. There was a clear correlation between the
P
app and the unbound brain/blood ratios determined by
in vivo microdialysis (BBMEC
r
=
0.99, Caco-2
r
=
0.91 and MDCKII-MDR1
r
=
0.85). Despite of the substantial differences in the absolute
in vitro P
app values and regardless of the method used (side-by-side vs. filter insert system), the capability of the
in vitro models to rank order drugs was similar. By this approach, thus, the additional value offered by the true endothelial cell model (BBMEC) remains obscure. The present results also highlight the need of both
in vitro as well as
in vivo methods in characterization of blood–brain barrier passage of new drug candidates. |
---|---|
ISSN: | 0378-5173 1873-3476 |
DOI: | 10.1016/j.ijpharm.2010.09.016 |